RNA sequencing of RBP4 or control treated cells

Purpose: The purpose of this study was to find the differentially expressed genes in RBP4 and control treated cells by transcriptome analysis (RNA-seq) for subsequent mechanism study. Methods: Illumina Novaseq™ 6000 was used to sequencing RBP4 and control-treated human umbilical vein endothelial cells.Genes differential expression analysis was performed by DESeq2 software between two different groups (and by edgeR between two samples). The genes with the parameter of false discovery rate (FDR) below 0.05 and absolute fold change ≥ 2 were considered differentially expressed genes. Differentially expressed genes were then subjected to enrichment analysis of GO functions and KEGG pathways.GO enrichment analysis provides all GO terms that significantly enriched in DEGs comparing to the genome background. Firstly all DEGs were mapped to GO terms in the Gene Ontology database (http://www.geneontology.org/), gene numbers were calculated for every term, significantly enriched GO terms in DEGs comparing to the genome background were defined by hypergeometric test. Results:The RNA-seq results showed that compared to the untreated HUVECs, RBP4 treatment resulted in significant changes in the gene expression, including 180 up-regulated and 53 down-regulated genes among a total number of 233 DEGs. GO enrichment were analyzed for relationships among all DEGs. Conclusions: Our study analyzed the mechanism of RBP4 on human umbilical vein endothelial cells and its possible pathway in detail by RNA-seq technique, and provided a basis for elucidating the damage of RBP4 on endothelial cells through large-scale gene screening.